Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115676) titled 'Study on the mechanism of SUZ12-YBX1 protein interaction in inhibiting ferroptosis through epigenetic regulation of the KEAP1/NRF2 signaling axis to promote chemotherapy resistance in pancreatic cancer' on Dec. 30, 2025.
Study Type: Observational study
Study Design:
Cross-sectional
Primary Sponsor: Huzhou Central Hospital
Condition:
pancreatic cancer
Intervention:
Drug-resistant group and non-drug-resistant group:None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-01-01
Target Sample Size: Drug-resistant group and non-drug-resistant group:6;Cancer and paracancerous grou...